Enliven Therapeutics (ELVN) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Enliven Therapeutics (NASDAQ: ELVN) in the last few weeks:

• 7/21/2026 – Enliven Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $59.00 to $67.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Enliven Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/9/2026 – Enliven Therapeutics had its price target raised by HC Wainwright from $56.00 to $64.00. They now have a “buy” rating on the stock.
• 7/1/2026 – Enliven Therapeutics had its price target raised by Stifel Nicolaus from $60.00 to $80.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Enliven Therapeutics had its price target raised by JonesTrading from $45.00 to $70.00. They now have a “buy” rating on the stock.
• 6/9/2026 – Enliven Therapeutics is now covered by Stifel Nicolaus. They set a “buy” rating and a $60.00 price target on the stock.
• 6/2/2026 – Enliven Therapeutics had its price target raised by Mizuho from $45.00 to $62.00. They now have an “outperform” rating on the stock.

Insider Activity

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the transaction, the director owned 41,884 shares in the company, valued at $2,114,723.16. This trade represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total value of $263,588.40. Following the sale, the chief financial officer directly owned 51,000 shares in the company, valued at $2,233,800. The trade was a 10.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 26,018 shares of company stock worth $1,113,888. 3.00% of the stock is owned by company insiders.

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.